Once-weekly somatrogon versus daily somatropin in pediatric growth hormone deficiency: A systematic review and meta-analysis.
Once-weekly somatrogon may offer a practical alternative to daily somatropin for children with growth hormone deficiency, but the clinical significance of the findings requires careful consideration.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This systematic review and meta-analysis compared once-weekly somatrogon with daily somatropin in children with growth hormone deficiency. The study measured IGF-1 standardized score (SDS), change from baseline in height SDS, height velocity, and adverse events. Results indicated a greater increase in IGF-1 SDS with somatrogon at multiple time points, but no significant difference in height SDS or height velocity was observed.
Abstract
<h4>Background</h4>Pediatric growth hormone (GH) deficiency is treated with daily somatropin injections, which may reduce adherence over long treatment periods. Somatrogon is a once-weekly long-acting GH designed to reduce treatment burden while maintaining efficacy and safety. This systematic review and meta-analysis compared once-weekly somatrogon with once-daily somatropin in children with GH deficiency.<h4>Methods</h4>We searched PubMed, Scopus, and Web of Science from inception to April 2026 for randomized controlled trials (RCTs) and comparative studies of prepubertal children with GH deficiency. Outcomes were IGF-1 standardized score (SDS), change from baseline in height SDS, height velocity, and adverse events. Random-effects meta-analysis was performed, with subgroup analyses by follow-up duration and sensitivity analyses to assess robustness using R software.<h4>Results</h4>A total of seven studies, including three RCTs, two retrospective real-world cohorts, and two post hoc analyses were included. Compared with daily somatropin, weekly somatrogon produced a significantly greater increase in IGF-1 SDS at 3, 6, 9, and 12 months, with a consistent effect across time points. The change from baseline in height SDS did not differ significantly between groups at any follow-up point. Height velocity was generally comparable, although a transient advantage for somatrogon was observed at 9 months. The rate of any adverse event was slightly lower in somatropin group, but did not reach statistical significance.<h4>Conclusion</h4>Once-weekly somatrogon is an effective and relatively safe alternative to daily somatropin in prepubertal children with GH deficiency, with the practical advantage of reduced injection frequency and potentially lower treatment burden.
Background
This paper addresses the treatment of pediatric growth hormone deficiency, which is traditionally managed with daily somatropin injections. Adherence to daily injections can be challenging over long treatment durations. Somatrogon, a once-weekly formulation, aims to reduce the treatment burden while maintaining efficacy and safety, making this comparison relevant for clinical practice.
Methods
The study conducted a systematic review and meta-analysis of randomized controlled trials and comparative studies involving prepubertal children with growth hormone deficiency. A total of seven studies were included, comprising three RCTs, two retrospective cohorts, and two post hoc analyses. Primary outcomes included IGF-1 SDS, height SDS change, height velocity, and adverse events, with analyses performed using random-effects meta-analysis.
Results
The analysis found a significantly greater increase in IGF-1 SDS for somatrogon at 3, 6, 9, and 12 months. Height SDS change did not show significant differences between the two groups at any follow-up. Height velocity was similar overall, with a transient advantage for somatrogon noted at 9 months. Adverse events were slightly lower in the somatropin group, but this difference was not statistically significant.
Interpretation
While the findings indicate a statistically significant increase in IGF-1 SDS for somatrogon, the clinical significance of this difference remains uncertain without clear evidence of improved height outcomes. The mixed study designs, including retrospective and post hoc analyses, introduce confounding factors that may limit the conclusions drawn. Practitioners should consider these limitations when interpreting the results for clinical application.
Key findings
- Greater increase in IGF-1 SDS at 3, 6, 9, and 12 months compared to daily somatropin, n=7 studies.
- No significant difference in height SDS change between groups at any follow-up point.
- Transient advantage in height velocity for somatrogon observed at 9 months.
- Rate of any adverse event slightly lower in somatropin group, but did not reach statistical significance.
Limitations
- Includes a mix of RCTs and observational studies.
- Small sample sizes in some included studies.
- Short follow-up duration may not capture long-term effects.
- Post hoc analyses may introduce bias.